Bruker (BRKR) Corporation announced the launch of iNTApharma, a label-free characterization platform that provides single-particle sensitivity for the quantitative analysis of nanoscale bioparticles in native aqueous media. “Introduced at SLAS 2026 in Boston, iNTApharma delivers size and concentration measurements within minutes, supporting research, therapy development and quality control workflows that require direct, native-state assessment of bio-nanoparticle populations without labeling or chemical modifications,” the company said.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker price target raised to $58 from $53 at Guggenheim
- Bruker price target raised to $53 from $40 at Citi
- Bruker: Solid Q4 Momentum and Reaffirmed 2026 Targets Underpin Buy Rating and Upside Potential
- Bruker clarifies regulatory filing status in recent 8-K
- Bruker sees Q4 preliminary revenue $965M-$970M, consensus $958.3M